Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia

Table 6 Multivariate logistic regression trend analysis: SP ^a -IPTp ^b doses (continuous variable) associated with outcomes of interest

Adjusted model ^c	Trend prevalence ratio estimate (95% CI ^d )	Trend p-value
Placental infection^e
Paucigravid	0.88 (0.77-1.04)	0.13
Multigravid	0.94 (0.76-1.16)	0.58
Low birth weight (<2,500 g)
Paucigravid	0.54 (0.33-0.90)	0.02
Multigravid	0.63 (0.41-0.97)	0.04
Preterm (<37 weeks)
Paucigravid	0.85 (0.62-1.17)	0.32
Multigravid	0.48 (0.34-0.69)	<0.0001
Composite birth outcome^f
Paucigravid	0.94 (0.77-1.15)	0.56
Multigravid	0.66 (0.53-0.82)	<0.001
Any infection^g
Paucigravid	0.89 (0.77-1.03)	0.13
Multigravid	0.95 (0.77-1.17)	0.63

^aSP = sulphadoxine pyrimethamine.
^bIPTp = intermittent preventive treatment for malaria in pregnancy.
^cModel adjusts for: Age group (<18, 18–35, >35), gravidity as an interaction term, sleeping under an ITN the last night at home, living in a home treated with IRS, urban, facility, delivered during the wet season, marital status.
^dCI = 95% confidence interval.
^ePlacental infection outcome: histopathology classes 1–4 vs class 5.
^fComposite birth outcome defined as infants born with any of: LBW, SGA, or preterm.
^gAny infection defined as pathology classes 1–4, blood smear positive (maternal, placental or cord blood).

ISSN: 1475-2875